YZYan Zou

Yan Zou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yan Zou has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Cai-Hua Xi

    MD. Associate Professor, Department of Intensive Care Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China

    1 shared publication
  • Changtai Zhu

    Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University

    1 shared publication
  • Duxin Ji

    Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University

    1 shared publication
  • Guangwei Xie

    Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University

    1 shared publication
  • Ji-Bin Xiong

    MD. Assistant Professor, Department of Hyperbaric Oxygen Therapy, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China

    1 shared publication
  • Jia Wen

    Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University

    1 shared publication

Latest Publications

  • Open Access

    Pheochromocytoma crisis complicated by disseminated intravascular coagulation and tumor rupture: A case report

    by Duxin Ji, Jiali Wang, Qinghua Tian, Qin Huang, Changtai Zhu, Guangwei Xie, Xiaojun Deng, Zhengchao Li, Pengzhen Liang, Rundong Zhang, et al.

    Pheochromocytoma may rarely present with pheochromocytoma multisystem crisis (PMC), and disseminated intravascular coagulation (DIC) is an uncommon manifestation. Their coexistence with spontaneous tumor rupture is particularly unusual and creates major diagnostic and therapeutic difficulty. We report a 27-year-old woman with spontaneously ruptured pheochromocytoma complicated by PMC and DIC. She initially presented with hyperglycemia, high-anion-gap metabolic acidosis, and hyperlactatemia, raising concern for diabetic ketoacidosis. Her condition then evolved rapidly, with marked blood pressure lability, pulmonary edema, shock, acute kidney and liver injury, respiratory failure, and pheochromocytoma-associated stress cardiomyopathy. Imaging showed a hemorrhagic adrenal mass with retroperitoneal hematoma. Laboratory testing demonstrated thrombocytopenia, hypofibrinogenemia, prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT), markedly elevated D-dimer, persistent abnormalities in thrombin-antithrombin III complex (TAT), plasmin–α2-plasmin inhibitor complex (PIC), tissue plasminogen activator–plasminogen activator inhibitor-1 complex (t-PAIC), and thrombomodulin (TM), and severe mixed hypocoagulability on thromboelastography. Plasma metanephrine, normetanephrine, and 3-methoxytyramine were markedly elevated, supporting the diagnosis of pheochromocytoma crisis. Because the immediate priority at presentation was control of active hemorrhage, transarterial embolization (TAE) was performed before pheochromocytoma had been fully recognized. Conventional preoperative optimization was not feasible because even minimal α-blockade worsened hemodynamics, and aggressive fluid loading risked aggravating pulmonary edema. The patient was managed with staged treatment including TAE, organ support, transfusion and coagulation-directed therapy, and delayed adrenalectomy after stabilization. She survived and subsequently underwent definitive surgery. This case shows that DIC, although rare in pheochromocytoma, may occur in the setting of tumor rupture and PMC. In unstable patients in whom immediate adrenalectomy and standard preoperative preparation are not possible, staged management with early TAE and delayed surgery may be a useful approach.

  • Open Access

    Effectiveness of Continuous Glucose Monitoring on Short-Term, In-Hospital Mortality Among Frail and Critically Ill Patients With COVID-19: Randomized Controlled Trial

    by Jiawei Shang, Ziming Yuan, Zuoyan Zhang, Quanhong Zhou, Yan Zou, Wei Wang

    Background: The use of continuous glucose monitoring (CGM) in the hospital setting is growing, with more patients using these devices at home, especially during the COVID-19 pandemic. Frail and critically ill patients with COVID-19 and previously normal glucose tolerance are also associated with variability in their glucose levels during their intensive care unit (ICU) stay. However, very limited evidence supports the use of CGM in ICU settings, especially among frail patients with COVID-19. Objective: We aimed to investigate the effectiveness of CGM on ICU-related outcomes among frail and critically ill patients with confirmed COVID-19. Methods: This was an exploratory, prospective, open-label, parallel, single-center, randomized controlled trial. A total of 124 patients was finally analyzed. The primary outcome was 28-day, in-ICU mortality. The secondary outcome included the length of ICU stay as well as the occurrence of hypoglycemia and severe hypoglycemia events. Results: The mean age was 78.3 (SD 11.5) years. The mean fasting glucose level and hemoglobin A1c level at baseline were 8.12 (SD 1.54) mmol/L and 7.2% (SD 0.8%), respectively. The percentage of participants with diabetes was 30.6% (38/124). The corresponding hazard ratio of the primary outcome in the intermittently scanned CGM (isCGM) group when compared with the point-of-care testing (POCT) group was 0.18 (95% CI 0.04-0.79). The average length of ICU stay was 10.0 (SD 7.57) days in the isCGM group and 14.0 (SD 6.86) days in the POCT group (P=.02). At the end of study period, the mean value of fasting glucose in the isCGM group and the POCT group was 6.07 (SD 0.63) mmol/L and 7.76 (SD 0.62) mmol/L, respectively (P=.01). A total of 207 hypoglycemia events (<3.9 mmol/L) was detected, with 43 in the isCGM group and 164 in the POCT group (P<.001). A total of 81 severe hypoglycemia events (<2.8 mmol/L) was detected, with 16 in the isCGM group and 65 in the POCT group (P<.001). The major adverse event in this study was bleeding in the puncture site, with a total of 6 occurrences in the isCGM group. During the follow-up, none of the participants dropped out because of bleeding in the puncture site. Conclusions: We found a significant clinical benefit from the use of CGM among frail and critically ill patients with COVID-19. These findings support the use of CGM in the ICU and might help with the extension of application in various in-hospital settings. Trial Registration: Chinese Clinical Trial Registry ChiCTR2200059733; https://www.chictr.org.cn/showproj.html?proj=169257


  • Open Access

    Comparison of the effects of albumin and crystalloid on mortality among patients with septic shock: systematic review with meta-analysis and trial sequential analysis

    by Yan Zou, Ke Ma, Ji-Bin Xiong, Cai-Hua Xi, Xiao-Jun Deng

    KEY WORDS: Albumins; Crystalloid solutions; Mortality; Shock, septic